Compass Therapeutics (NASDAQ:CMPX) Announces Earnings Results

Compass Therapeutics (NASDAQ:CMPX) announced its quarterly earnings data on Thursday. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01, FiscalAI reports.

Compass Therapeutics Trading Up 2.5%

CMPX traded up $0.14 during trading on Thursday, reaching $5.83. 453,195 shares of the company’s stock were exchanged, compared to its average volume of 2,287,071. The firm has a fifty day moving average price of $5.88 and a two-hundred day moving average price of $4.77. The stock has a market capitalization of $1.04 billion, a PE ratio of -12.96 and a beta of 1.48. Compass Therapeutics has a one year low of $1.33 and a one year high of $6.88.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. LPL Financial LLC lifted its stake in shares of Compass Therapeutics by 4.7% in the 4th quarter. LPL Financial LLC now owns 44,470 shares of the company’s stock valued at $239,000 after purchasing an additional 2,000 shares during the period. Victory Capital Management Inc. grew its stake in Compass Therapeutics by 20.6% during the third quarter. Victory Capital Management Inc. now owns 12,652 shares of the company’s stock worth $44,000 after purchasing an additional 2,164 shares during the period. Focus Partners Wealth increased its holdings in Compass Therapeutics by 16.2% in the third quarter. Focus Partners Wealth now owns 15,805 shares of the company’s stock worth $56,000 after purchasing an additional 2,206 shares in the last quarter. Invesco Ltd. lifted its stake in Compass Therapeutics by 5.3% in the fourth quarter. Invesco Ltd. now owns 63,901 shares of the company’s stock valued at $343,000 after buying an additional 3,245 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in Compass Therapeutics by 1.9% in the third quarter. Dimensional Fund Advisors LP now owns 175,556 shares of the company’s stock valued at $619,000 after buying an additional 3,329 shares during the period. 68.43% of the stock is owned by institutional investors.

Analysts Set New Price Targets

CMPX has been the topic of several research reports. Leerink Partners upgraded shares of Compass Therapeutics to a “strong-buy” rating in a report on Wednesday, November 26th. Canaccord Genuity Group set a $13.00 price target on Compass Therapeutics in a research note on Wednesday, February 4th. Cantor Fitzgerald began coverage on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. They set an “overweight” rating on the stock. Citizens Jmp set a $10.00 target price on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $30.00 price target on shares of Compass Therapeutics in a report on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Compass Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $13.36.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.